


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented): A combination comprising two anti-epileptics selected from carboxamides and an AMPA antagonist of formula I



wherein

R₁ is hydroxy or (C₁₋₄)alkyl,

R₂ is hydrogen or (C₁₋₄)alkyl,

R₃ is hydrogen, (C₁₋₄) alkyl, fluorine, chlorine, bromine, trifluoromethyl, cyano or nitro, and


X is (C₁₋₈)alkylene, (C₁₋₆)alkylidene, (C₁₋₆)alkylene(C₃₋₆)cycloalkylene or (C₁₋₆)alkylene-(C₃₋₆)cycloalkylidene

in which the anti-epileptics are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier.

2. (Previously Presented): The combination according to claim 1 which is a combined preparation or a pharmaceutical composition.

3-5. (Canceled)

6. (Currently Amended): The combination according to claim 15 wherein the carboxamide is selected from the group consisting of carbamazepine, oxcarbazepine, 10-hydroxy-10,11-dihydrocarbamazepine and the compounds of formula II



wherein R₁' represents acetoxy.

7. (Currently Amended): The combination according to claim 15, wherein in the formula I R₁ is hydroxy, R₂ is hydrogen, R₃ is nitro and X is methylene.
8. (Canceled)
9. (Withdrawn): A method of treating a condition in a warm-blooded animal wherein said condition is selected from the group consisting of epilepsy and seizures comprising administering to the animal a combination comprising two anti-epileptics according to claims 1 wherein said anti-epileptics are present in quantities which are jointly therapeutically effective against epilepsy and in which the compounds can optionally be present in the form of their pharmaceutically acceptable salts.
10. (Previously Presented): A pharmaceutical composition comprising two anti-epileptics according to claim 1, wherein said anti-epileptics are present in quantities which are jointly therapeutically effective against epilepsy, and at least one pharmaceutically acceptable carrier.
- 11-12. (Cancelled)
13. (Previously Presented): A kit comprising a combination of two anti-epileptics according to claim 1 in unit dosage form for simultaneous, separate or sequential administration to a warm blooded animal according to method of treating a condition in said animal wherein said condition is selected from the group consisting of epilepsy and seizures.